Juergen Kurz – General Manager, HEUFT China
Juergen Kurz takes us through HEUFT’s unique technology that is revolutionizing the quality of packaging in the pharmaceutical industry in a country, China, where quality compliance is now an issue. …
Address: Guilinyang Develops Area, Haikou, Hainan province, P.R.China 571127
Tel: +86 898 6571 8261
Hainan Yishun Pharmaceutical Co,. Ltd is a modern large pharmaceutical enterprise, which is established in Jun 6, 2003, with a registered capital of 50 million RMB (about 7.8 million dollars) and fixed asserts of 100 million RMB (about 15.7 million dollars). Company is located in Guilinyang Develops Area, Haikou, Hainan province, P.R.China. The plant area is more than 12,000 square meters, with a staff of more than 200. There are several production lines: powder for injection, new-type solid dosage form, APIs, small capacity injection and lyophilized powder for injection. All the production lines, staff and facility are organized and built strictly by GMP standard, and pass through and obtain new version SFDA-GMP certificate. On the aspect of quality control and quality assurance, we start with a high standard to build new plants, to introduce advanced production equipments, to be equipped with state-level drug quality testing instruments. All the efforts we make are to establish a comprehensive quality control and quality assurance system to supervise every link of drug production, sale and recall to ensure product quality. The whole process is in strict accordance with GMP requirements to implement and manage.
For overseas market, we will focus on promoting products of lyophilized powder for injection and sterile powder for injection. There is a products catalog available for international registration and sale. The overseas target markets of the company are Southeast Asia, Africa and Latin America. The company is looking for long-term partners and agents to create business opportunities and to achieve a win-win situation.
Juergen Kurz takes us through HEUFT’s unique technology that is revolutionizing the quality of packaging in the pharmaceutical industry in a country, China, where quality compliance is now an issue. …
China’s new Amended Drug Administration Law is being enacted to strengthen and streamline its regulation of the pharmaceutical industry. The amended law seeks to address prominent problems in the pharmaceutical…
China’s new Amended Drug Administration Law is being enacted to strengthen and streamline its regulation of the pharmaceutical industry as well as address prominent problems such as counterfeit drugs, substandard…
Tao Chen, head of business development of Absea and CEO of the new spin-out Agsea, is entering the world of immunodiagnostics with a comprehensive panel of IHC antibodies in the…
China’s booming pharmaceutical industry has been rapidly expanding to become the second largest pharmaceutical market globally. The following are the top ten Chinese pharma companies from 2018, with revenues reaching over…
Dr CJ Wang, CEO of Frontier Biotech, shares his exciting ten-year journey with Frontier and their distinctive focus on HIV drug development, with their flagship compound, Aikening®, launched in China…
Dr Laura Benjamin, CEO of Oncologie, shares the rationale behind their exceptional decision to simultaneously establish offices in both the US and China; their unique biomarker approach focusing on the…
Shirley Xu, president of Baxter Greater China, reflects on her extraordinary 26-year (and counting) career with Baxter China, including her perspectives on the success factors behind Baxter’s growth in the…
John Moller, CEO; and Yooni Kim, executive director of Asia operations, for Novotech, share the competitive positioning of Novotech as a full-service CRO for biotech companies interested in the Asia-Pacific…
China’s roll-out of a 25-province expansion to the 4+7 pilot procurement scheme has seen pharma companies scrambling to cut prices for their drugs even further in the latest bidding war.…
Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative medicines; their focus on genitourinary…
Dr Irwin Wang, CEO of Reistone Biopharma, shares her motivations behind the establishment of the company, their extremely productive collaboration with Jiangsu Hengrui (China’s largest pharma company by market capitalization),…
See our Cookie Privacy Policy Here
